… The multivalent bispecific … live SARS-CoV-2 we employed a classical virus neutralization
assay and confirmed that both sybodies successfully inhibited cell entry by infectious SARS-CoV…

… novel animal model of SARS-CoV-2 infection with lung inflammation, CoV-X2 … bispecific
antibodies is feasible and effective, combining into a single molecule the advantages of antibody …

… Administration of neutralizing antibodies (nAbs) has proved to be effective by providing
immediate protection against SARS‐CoV‐2. However, dual strategies combining virus …

… mAbs 7–9, additional strategies to combat SARS-CoV-2 have been 73 investigated. One
of … antibody-like constructs, such as bispecific antibodies (bsAbs). 75 Different SARS-CoV-2 …

… -29 and 16-3022 against SARS-CoV-2 original strain and Omicron … SARS-CoV RBD-targeted
scFv S3022 could play a synergistic role with other SARS-CoV-2 RBD-targeted antibodies …

… In this paper, we highlight RBT-0813, a synthetic VHH bispecific antibody capable of binding
and neutralizing the SARS-CoV-2 Delta and Omicron variants. This bispecific antibody links …

… re-neutralization abilities against mutated SARS-CoV-2 variants 30,31,… antibodies against
escaping variants of SARS-CoV-2, such as antibody cocktails 53,54 and bispecific antibodies …

… Finally, BsAb targeting of the nuclear plasmid protein of the SARS coronavirus immunoassay
antigen is superior to that by MoAb in terms of specificity, sensitivity, and signal strength …

… Bispecific antibodies (BsAbs) have been posited as potential cancer therapeutic agents
for decades but have only recently begun to bear fruit. BsAbs show several advantages [5]: (1) …

… Like SARS-CoV, MERS-CoV is an enveloped virus using its spike (S) protein to enter target
… To generate the bispecific antibody-peptide inhibitor, the MERS-CoV S2-derived peptide …